FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2032920306> ?p ?o ?g. }

• W2032920306 endingPage "247" @default.
• W2032920306 startingPage "241" @default.
• W2032920306 abstract "BACKGROUND: Several aromatase inhibitor studies have reported variations in the inhibitory potency of these agents that could lead to differences in clinical outcomes. In the current study, the authors formally evaluated the activity of anastrozole and exemestane in postmenopausal women with hormone-responsive, advanced breast cancer. METHODS: Postmenopausal women who had measurable disease according to Response Evaluation Criteria in Solid Tumors and had not received previous endocrine therapy for advanced breast cancer were randomized to receive either oral exemestane 25 mg daily or oral anastrozole 1 mg daily until they had disease progression. The primary endpoint was the objective response rate (ORR), and secondary endpoints included the clinical benefit rate (CBR), time to progression (TTP), overall survival, and safety. Crossover to the other aromatase inhibitor was permitted at the time of disease progression; ORR, CBR, and TTP after second-line treatment also were explored. RESULTS: In total, 103 patients were enrolled. The median patient age was 71.6 years, 52.4% of patients had visceral disease, and 75.8% of patients had ≥2 disease sites. Half of the patients had received previous tamoxifen, and 60% had received previous chemotherapy. The efficacy observed in the exemestane and anastrozole groups was an ORR of 36.2% and 46%, respectively; a CBR of 59.6% and 68%, respectively, and a TTP of 6.1 months and 12.1 months, respectively. At progression, 28 patients crossed over to the other aromatase inhibitor, including 16 patients who switched to exemestane (CBR, 43.7%; TTP, 4.4 months) and 12 patients who switched to anastrozole (CBR, 8.3%; TTP, 2 months). Both drugs were generally well tolerated, and no study drug-related serious adverse events were reported. CONCLUSIONS: In this phase 2 randomized trial, no significant differences in clinical activity were observed in favor of exemestane to justify a superiority phase 3 trial design in the first-line setting. Cancer 2012;. © 2011 American Cancer Society." @default.
• W2032920306 created "2016-06-24" @default.
• W2032920306 creator A5008504309 @default.
• W2032920306 creator A5027875773 @default.
• W2032920306 creator A5030451537 @default.
• W2032920306 creator A5033909513 @default.
• W2032920306 creator A5035054317 @default.
• W2032920306 creator A5035792370 @default.
• W2032920306 creator A5039927103 @default.
• W2032920306 creator A5040451692 @default.
• W2032920306 creator A5041550448 @default.
• W2032920306 creator A5062100063 @default.
• W2032920306 creator A5075755020 @default.
• W2032920306 creator A5075882477 @default.
• W2032920306 creator A5080310093 @default.
• W2032920306 creator A5090790623 @default.
• W2032920306 date "2011-06-29" @default.
• W2032920306 modified "2023-10-04" @default.
• W2032920306 title "Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer" @default.
• W2032920306 cites W1605523334 @default.
• W2032920306 cites W1781289545 @default.
• W2032920306 cites W1848530042 @default.
• W2032920306 cites W1972365816 @default.
• W2032920306 cites W1989958491 @default.
• W2032920306 cites W1991981105 @default.
• W2032920306 cites W1995662976 @default.
• W2032920306 cites W1998463105 @default.
• W2032920306 cites W2000366267 @default.
• W2032920306 cites W2027630405 @default.
• W2032920306 cites W2062485056 @default.
• W2032920306 cites W2102620699 @default.
• W2032920306 cites W2138571195 @default.
• W2032920306 cites W2139248078 @default.
• W2032920306 cites W2152591722 @default.
• W2032920306 cites W2165819904 @default.
• W2032920306 cites W2168030291 @default.
• W2032920306 cites W2169077182 @default.
• W2032920306 cites W2394592505 @default.
• W2032920306 doi "https://doi.org/10.1002/cncr.26299" @default.
• W2032920306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21717449" @default.
• W2032920306 hasPublicationYear "2011" @default.
• W2032920306 type Work @default.
• W2032920306 sameAs 2032920306 @default.
• W2032920306 citedByCount "26" @default.
• W2032920306 countsByYear W20329203062012 @default.
• W2032920306 countsByYear W20329203062013 @default.
• W2032920306 countsByYear W20329203062014 @default.
• W2032920306 countsByYear W20329203062015 @default.
• W2032920306 countsByYear W20329203062016 @default.
• W2032920306 countsByYear W20329203062017 @default.
• W2032920306 countsByYear W20329203062018 @default.
• W2032920306 countsByYear W20329203062019 @default.
• W2032920306 countsByYear W20329203062020 @default.
• W2032920306 countsByYear W20329203062021 @default.
• W2032920306 countsByYear W20329203062022 @default.
• W2032920306 crossrefType "journal-article" @default.
• W2032920306 hasAuthorship W2032920306A5008504309 @default.
• W2032920306 hasAuthorship W2032920306A5027875773 @default.
• W2032920306 hasAuthorship W2032920306A5030451537 @default.
• W2032920306 hasAuthorship W2032920306A5033909513 @default.
• W2032920306 hasAuthorship W2032920306A5035054317 @default.
• W2032920306 hasAuthorship W2032920306A5035792370 @default.
• W2032920306 hasAuthorship W2032920306A5039927103 @default.
• W2032920306 hasAuthorship W2032920306A5040451692 @default.
• W2032920306 hasAuthorship W2032920306A5041550448 @default.
• W2032920306 hasAuthorship W2032920306A5062100063 @default.
• W2032920306 hasAuthorship W2032920306A5075755020 @default.
• W2032920306 hasAuthorship W2032920306A5075882477 @default.
• W2032920306 hasAuthorship W2032920306A5080310093 @default.
• W2032920306 hasAuthorship W2032920306A5090790623 @default.
• W2032920306 hasBestOaLocation W20329203061 @default.
• W2032920306 hasConcept C121608353 @default.
• W2032920306 hasConcept C126322002 @default.
• W2032920306 hasConcept C143998085 @default.
• W2032920306 hasConcept C203092338 @default.
• W2032920306 hasConcept C2775860665 @default.
• W2032920306 hasConcept C2775930923 @default.
• W2032920306 hasConcept C2776166826 @default.
• W2032920306 hasConcept C2776215463 @default.
• W2032920306 hasConcept C2777176818 @default.
• W2032920306 hasConcept C2778504769 @default.
• W2032920306 hasConcept C29456083 @default.
• W2032920306 hasConcept C530470458 @default.
• W2032920306 hasConcept C535046627 @default.
• W2032920306 hasConcept C71924100 @default.
• W2032920306 hasConceptScore W2032920306C121608353 @default.
• W2032920306 hasConceptScore W2032920306C126322002 @default.
• W2032920306 hasConceptScore W2032920306C143998085 @default.
• W2032920306 hasConceptScore W2032920306C203092338 @default.
• W2032920306 hasConceptScore W2032920306C2775860665 @default.
• W2032920306 hasConceptScore W2032920306C2775930923 @default.
• W2032920306 hasConceptScore W2032920306C2776166826 @default.
• W2032920306 hasConceptScore W2032920306C2776215463 @default.
• W2032920306 hasConceptScore W2032920306C2777176818 @default.
• W2032920306 hasConceptScore W2032920306C2778504769 @default.
• W2032920306 hasConceptScore W2032920306C29456083 @default.
• W2032920306 hasConceptScore W2032920306C530470458 @default.
• W2032920306 hasConceptScore W2032920306C535046627 @default.

• next